Sept. 2, 2020 — There’s no proof to aid the use of convalescent plasma to handle COVID-19 individuals, and medical professionals should not take into account it a standard of care right up until much more study is finished, a U.S. Nationwide Institutes of Wellness skilled panel said Tuesday.

“There are insufficient facts to advocate either for or versus the use of convalescent plasma for the treatment of COVID-19,” in accordance to a assertion posted on the NIH site by the panel of much more than three dozen industry experts, CNN documented.

“Convalescent plasma should not be considered standard of care for the treatment of individuals with COVID-19,” said the committee, which evaluates treatments for the new coronavirus.

Convalescent plasma is antibody-laden serum from the blood of individuals who’ve recovered from an an infection. The theory is that giving this plasma to new COVID-19 individuals will enhance their immune response, CNN documented.

Last week, the U.S. Food and Drug Administration granted unexpected emergency use authorization for the use of convalescent plasma for the treatment of COVID-19.

“Future, effectively-controlled, sufficiently run randomized trials are needed to establish no matter whether convalescent plasma is efficient and safe and sound for the treatment of COVID-19. Associates of the public and health care suppliers are inspired to participate in these possible clinical trials,” the skilled panel mentioned.

WebMD News from HealthDay


Copyright © 2013-2020 HealthDay. All legal rights reserved.